Glioblastoma is a dangerous brain malignancy known for its quick growth and insensitivity to conventional treatments. Research are constantly underway to identify new treatment strategies, and recently, a novel biomarker named LCA168 has emerged as a potential focus for GBM treatment. LCA168 is a protein that is abundantly produced in glioblastoma